Answers are grounded in this paper and cite their sources.
Randomized trial reveals treatment intensity impacts DLBCL outcomes, suggesting social factors influence prognosis.
Although diffuse large B-cell lymphoma (DLBCL) is curable for many patients with frontline immunochemotherapy, real-world outcomes often fall short of those reported in clinical trials. The pivotal...
No takes yet. Share an insight, caveat, or question.
Abuhelwa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: